Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Schuster

Showing results (151-160 of 173) with videos related to

Pageof 18
Sort By:
European Journal of Nuclear Medicine and Molecular Imaging|April 20, 2016
Recurrent prostate cancer detection with anti-3-[(18)F]FACBC PET/CT: comparison with CTOluwaseun A Odewole, Funmilayo I Tade, Peter T Nieh, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 31, 2021
Salvage Radiotherapy Management Decisions in Postprostatectomy Patients with Recurrent Prostate Cancer Based on <sup>18</sup>F-Fluciclovine PET/CT GuidanceOlayinka A Abiodun-Ojo, Ashesh B Jani, Akinyemi A Akintayo, et al.
Molecular Imaging and Biology|October 27, 2010
Pilot evaluation of anti-1-amino-2-[18F] fluorocyclopentane-1-carboxylic acid (anti-2-[18F] FACPC) PET-CT in recurrent prostate carcinomaBital Savir-Baruch, David M Schuster, Nashwa Jarkas, et al.
European Urology|July 6, 2023
Diagnostic Performance and Safety of Positron Emission Tomography with <sup>18</sup>F-rhPSMA-7.3 in Patients with Newly Diagnosed Unfavourable Intermediate- to Very-high-risk Prostate Cancer: Results from a Phase 3, Prospective, Multicentre Study (LIGHTHOUSE)Devaki Shilpa Surasi, Matthias Eiber, Tobias Maurer, et al.
Journal of the American College of Radiology : JACR|May 26, 2023
ACR Appropriateness Criteria® Post-Treatment Follow-up of Prostate Cancer: 2022 Update, Baris Turkbey, Aytekin Oto, et al.
Nature Methods|March 10, 2015
Whole-body immunoPET reveals active SIV dynamics in viremic and antiretroviral therapy-treated macaquesPhilip J Santangelo, Kenneth A Rogers, Chiara Zurla, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 3, 2014
Anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid: physiologic uptake patterns, incidental findings, and variants that may simulate diseaseDavid M Schuster, Cristina Nanni, Stefano Fanti, et al.
American Journal of Nuclear Medicine and Molecular Imaging|January 24, 2013
Characterization of primary prostate carcinoma by anti-1-amino-2-[(18)F] -fluorocyclobutane-1-carboxylic acid (anti-3-[(18)F] FACBC) uptakeDavid M Schuster, Pooneh A Taleghani, Peter T Nieh, et al.
Journal of the American College of Radiology : JACR|November 6, 2020
ACR Appropriateness Criteria® Recurrent Lower Urinary Tract Infections in Females, Aradhana M Venkatesan, Aytekin Oto, et al.
Cancer|April 16, 2026
Inflammatory biomarkers have a prognostic role in patients with metastatic castration-resistant prostate cancer treated with Lutetium-177-PSMA-617Margo B Gerke, Angelo Marra, Yuan Liu, et al.
Pageof 18

Showing results (151-160 of 173) with videos related to

Sort By:
Pageof 18
European Journal of Nuclear Medicine and Molecular Imaging|April 20, 2016
Recurrent prostate cancer detection with anti-3-[(18)F]FACBC PET/CT: comparison with CTOluwaseun A Odewole, Funmilayo I Tade, Peter T Nieh, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 31, 2021
Salvage Radiotherapy Management Decisions in Postprostatectomy Patients with Recurrent Prostate Cancer Based on <sup>18</sup>F-Fluciclovine PET/CT GuidanceOlayinka A Abiodun-Ojo, Ashesh B Jani, Akinyemi A Akintayo, et al.
Molecular Imaging and Biology|October 27, 2010
Pilot evaluation of anti-1-amino-2-[18F] fluorocyclopentane-1-carboxylic acid (anti-2-[18F] FACPC) PET-CT in recurrent prostate carcinomaBital Savir-Baruch, David M Schuster, Nashwa Jarkas, et al.
European Urology|July 6, 2023
Diagnostic Performance and Safety of Positron Emission Tomography with <sup>18</sup>F-rhPSMA-7.3 in Patients with Newly Diagnosed Unfavourable Intermediate- to Very-high-risk Prostate Cancer: Results from a Phase 3, Prospective, Multicentre Study (LIGHTHOUSE)Devaki Shilpa Surasi, Matthias Eiber, Tobias Maurer, et al.
Journal of the American College of Radiology : JACR|May 26, 2023
ACR Appropriateness Criteria® Post-Treatment Follow-up of Prostate Cancer: 2022 Update, Baris Turkbey, Aytekin Oto, et al.
Nature Methods|March 10, 2015
Whole-body immunoPET reveals active SIV dynamics in viremic and antiretroviral therapy-treated macaquesPhilip J Santangelo, Kenneth A Rogers, Chiara Zurla, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 3, 2014
Anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid: physiologic uptake patterns, incidental findings, and variants that may simulate diseaseDavid M Schuster, Cristina Nanni, Stefano Fanti, et al.
American Journal of Nuclear Medicine and Molecular Imaging|January 24, 2013
Characterization of primary prostate carcinoma by anti-1-amino-2-[(18)F] -fluorocyclobutane-1-carboxylic acid (anti-3-[(18)F] FACBC) uptakeDavid M Schuster, Pooneh A Taleghani, Peter T Nieh, et al.
Journal of the American College of Radiology : JACR|November 6, 2020
ACR Appropriateness Criteria® Recurrent Lower Urinary Tract Infections in Females, Aradhana M Venkatesan, Aytekin Oto, et al.
Cancer|April 16, 2026
Inflammatory biomarkers have a prognostic role in patients with metastatic castration-resistant prostate cancer treated with Lutetium-177-PSMA-617Margo B Gerke, Angelo Marra, Yuan Liu, et al.
Pageof 18